A 32-year-old man with CML in second chronic phase developed primary graft failure following matched unrelated donor transplantation using cryopreserved marrow cells. He was successfully regrafted within 60 days from a second fully matched donor using a nonmyeloablative conditioning regimen, with minimal toxicity. He remains in complete haematological, cytogenetic and molecular remission 2 years after second transplant. We believe that reduced intensity or 'minitransplants' may be preferable for patients requiring second allografts which are usually associated with a high transplant-related mortality. Bone Marrow Transplantation (2001) 27, 547-549. Keywords: graft failure; MUD BMT; second transplant; non-myeloablative conditioning Primary graft failure is a devastating and often fatal complication of unrelated donor transplantation which occurs in 4-14% of reported cases depending on the conditioning protocol used.
Primary graft failure is a devastating and often fatal complication of unrelated donor transplantation which occurs in 4-14% of reported cases depending on the conditioning protocol used. 1, 2 One recent large study from the NMDP reported a 9.7% incidence of primary graft failure following non-T cell-depleted unrelated donor transplants. 3 Known risk factors for graft failure include HLA mismatched graft, 4 volunteer unrelated donor transplantation, 5 low marrow cell dose 6 and T cell depletion of the graft. 7 Although a second unrelated donor transplant can result in successful engraftment and lead to prolonged survival, 8 overall, the outcome of second transplants is poor due mainly to a high transplant-related toxicity, with many patients succumbing to infection from prolonged neutropenia. Indeed, the IBMTR reported only a 7% disease-free survival and almost 70% TRM in patients retransplanted from sibling donors within 6 months of the initial transplant. 9 In an attempt to obtain rapid engraftment with minimal toxicity we elected to use a non-myeloablative conditioning regimen prior to regrafting from a second unrelated donor.
Case history
A 32-year-old male presented in March 1998 with right upper quadrant pain due to massive splenomegaly. A full blood count revealed a Hb of 7.7 g/dl, WBC of 102 × 10 9 /l and platelets of 228 × 10 9 /l and a bone marrow aspirate confirmed the diagnosis of chronic myeloid leukaemia in chronic phase. Cytogenetic analysis at diagnosis revealed the standard Philadelphia translocation and RT-PCR confirmed a standard p210 BCR-ABL transcript. Cryopreservation of chronic phase cells was performed after routine leucapheresis using a Baxter (Newbury, UK) CS3000 cell separator machine. Initial treatment with hydroxyurea was commenced, and following this the patient was started on alpha-interferon. Within 2 months he had developed profound thrombocytopenia (platelets 26 × 10 9 /l) and was noted to have large numbers of circulating myeloblasts on the peripheral blood film (WBC 65 × 10 9 /l). A further bone marrow aspirate with immunophenotyping confirmed transformation to myeloid blast crisis and cytogenetics revealed an additional chromosomal translocation t(8;12) in 10/12 cells analysed. The patient underwent two courses of AMLtype chemotherapy with the FLAG regimen (fludarabine, high-dose cytarabine and G-CSF) 10 and achieved a second chronic phase while an unrelated donor search was undertaken since there was no sibling donor. Two possible donors were identified by the Anthony Nolan Bone Marrow Registry who were fully matched by high resolution typing at the A,B,C, DRB1 and DQB1 loci and the BMT was scheduled for July 1998. Unfortunately, neither donor was available for harvesting on the planned date due to extensive travel abroad. Since we did not wish to delay the transplant it was decided to harvest the available donor the week before the planned transplant date and cryopreserve the marrow for reinfusion the following week. The patient received standard conditioning consisting of pretransplant ATG (Thymoglobuline; Sangstat, Windsor, UK), cyclophosphamide (120 mg/kg) and fractionated TBI (14.4 Gy). Cyclosporin A and short-course methotrexate were used for GVHD prophylaxis. 11 The marrow was thawed and reinfused uneventfully but the post-freeze cell dose received was low at 0.74 × 10 8 mononuclear cells/kg. The post-transplant course was complicated by mucositis requiring opiate analgesia and early neutropenic sepsis which resolved with standard broad-spectrum antibiotics. Haemopoietic growth factor support was routinely commenced with G-CSF 300 g from day +9 post transplant. Primary graft failure was suspected when absolute neutropenia (ANC Ͻ0.01 × 10 9 /l) persisted on day +16 post transplant and was confirmed by the demonstration of marrow hypoplasia (Ͻ10% cellularity) together with a peripheral blood ANC Ͻ0.01 × 10 9 /l on day +21 post transplant. At this time point the patient was 'rescued' by reinfusion of autologous cryopreserved CML cells (CD34 + cell dose 3.53 × 10 6 /kg) and the cyclosporin A was withdrawn. Over the next few days his clinical condition rapidly deteriorated despite broadspectrum antibiotic and anti-fungal drugs, due to severe disseminated bacterial sepsis requiring removal of a tunnelled central line. In addition, he developed a probable fungal chest infection and impaired renal function. On the 40th day post transplant (19 days after reinfusion of autologous CML cells) there was evidence of some haemopoietic recovery with a peripheral blood ANC rising to 0.1 × 10 9 /l, and gradual resolution of sepsis occurred over the following few days. Repeat bone marrow at this stage confirmed 100% Philadelphia-positive cells with no evidence of mixed chimerism. Despite this clinical improvement there was no further haemopoietic recovery over the following 2 weeks with the patient remaining blood and platelet dependent with a peripheral blood ANC never exceeding 0.2 × 10 9 /l. It was therefore decided to proceed directly to a second unrelated donor BMT using the other fully HLA-A, B and DR matched donor. In view of the potential toxicity of a second transplant so soon after the first it was decided to use a reduced intensity non-myeloablative conditioning regimen. For this purpose he received Campath 1G anti-CD52 antibody for 5 days pretransplant together with fludarabine and cytarabine (FLAG regimen) and had the second marrow infused 58 days following the initial transplant (nucleated cell dose 2.97 × 10 8 /kg). GVHD prophylaxis was with cycloporin A alone. He tolerated this treatment without any major toxicity and engrafted rapidly, reaching neutrophils Ͼ0.5 × 10 9 /l by the 15th post-transplant day, and was discharged home on the 20th posttransplant day.
His post-transplant course has been complicated by CMV reactivation requiring gancyclovir therapy and the development of limited cutaneous chronic GVHD which has resolved following steroid therapy. Cytogenetic analysis performed 3 months following the second transplant revealed no evidence of the Phildelphia chromosome and he became BCR-ABL negative by RT-PCR at 9 months post transplant and remains in molecular remission 2 years post transplant. Immune reconstitution has been slow, taking 18 months to achieve an absolute CD4 + count of 200 × 10 6 /l.
Discussion
Primary graft failure is a recognised life-threatening complication following unrelated donor transplantation. Using our current standard conditioning protocol for unrelated donor transplantation which involves in vivo T cell depletion using serotherapy 11 we have only observed primary graft failure in one previous patient who received a mismatched graft. Although previous reports have not demonstrated any adverse effect of cryopreservation of allogeneic BM on haemopoietic stem cell function or speed of engraftment, 12 we speculate that the cause of the graft failure in this patient was related to the low marrow cell dose exacerbated by the process of cryopreservation and thawing of the marrow.
Following the diagnosis of graft failure in our patient it was felt that the quickest and most reliable way of restoring marrow function was to reinfuse autologous back up cells. However, this approach only partially restored haemopoietic function. The reason for this poor haematological recovery following autologous rescue is not clear although a previous report suggests that full restoration of blood parameters may be protracted in this setting. 13 In view of this incomplete haemopoietic recovery and the perceived risk of further rapid transformation to blast crisis it was felt necessary to proceed directly to a second transplant. Fortunately, an alternative fully matched donor was previously known to be available, allowing us to overcome the practical difficulties of rescheduling a second procedure in such a short time frame.
The choice of a preparative regimen for a second procedure is difficult since intensive conditioning may lead to considerable regimen-related toxicity. Although some reports of successful 'booster' doses of marrow or peripheral blood stem cells have been reported following graft failure without preparative treatment 14 it was felt that additional conditioning was necessary in our patient in view of the reinfusion of autologous cells. We elected to use a reduced intensity non-myeloablative but highly immunosuppressive regimen in order to minimise toxicity and obtain rapid engraftment. A similar regimen without the monoclonal antibody has previously been successfully used as conditioning prior to second transplants from sibling donors following relapse after initial allogeneic transplantation. 15 In our patient this treatment was very well tolerated and allowed rapid engraftment. We suggest that such reduced intensity or 'mini-transplants' may be preferable for patients requiring second allografts which are usually associated with a high transplant-related mortality.
